glp-1 kidney side effects Renal of receptor agonists and tirzepatide in individuals with type 2 diabetes: seeds of a promising future | Endocrine Real-World Evidence for GLP-1 Receptor

GLP-1s for Chronic Kidney Disease GLP-1s for Advanced Liver Disease In August 2025, the FDA approved Wegovy (semaglutide) to treat adults with a type of liver disease called metabolic-associated steatohepatitis (MASH) with moderate to advanced liver scarring (fibrosis), when used alongside diet and exercise

5 Retatrutide and tirzepatide have demonstrated significant improvements in lipid profiles and insulin sensitivity, making them valuable for adolescents at risk for metabolic syndrome

N Engl J Med (2022) 387(12):106374

Health 10 min read Semaglutide & Muscle Loss: What GLP-1 Drugs Do to Your Body The Problem: Weight Doesnt Tell the Whole Story GLP-1 therapy conversations typically focus on blood sugar control and body weight reduction

Weight management GLP-1s have been seen as gamechangers from a clinical standpoint, helping people shed significant weight when paired with lifestyle modification